BioDiscovery 6 Discloses 8.8% Stake in Inventiva (IVA)

Rhea-AI Filing Summary

Inventiva S.A. Schedule 13G/A reports that BioDiscovery 6 FPCI is the record holder of 12,296,295 ordinary shares, representing 8.8% of the company’s ordinary share class based on 139,151,274 shares outstanding as of May 7, 2025. Voting and dispositive authority for those shares is exercised by Andera Partners as BioDiscovery 6’s management company, and the managing partners Stephane Bergez and Francois Xavier Mauron are identified as having shared voting and dispositive power. Each Reporting Person reports 0 sole voting or dispositive power and 12,296,295 shared voting and dispositive power as of June 30, 2025.

Positive

• Material ownership disclosed: BioDiscovery 6 reports 12,296,295 shares, equal to 8.8% of ordinary shares, meeting SEC disclosure thresholds.
• Clear chain of authority: Filing specifies Andera Partners as the management company with named managing partners, improving transparency.
• Certification of passive intent: Reporting Persons certify the stake was not acquired to change or influence control, consistent with Schedule 13G/A use.

Negative

• None.

Insights

Financial Analyst

TL;DR: A 8.8% stake is disclosed with shared control through an investment vehicle; this is material ownership but not an outright control position.

The filing shows BioDiscovery 6 holds 12,296,295 ordinary shares, equal to 8.8% of outstanding ordinary shares. Andera Partners, via its management role, and two managing partners report shared voting and dispositive power, with no sole power reported. For investors, this is a material passive stake disclosure under Schedule 13G/A thresholds; it signals a significant institutional investor with centralized decision-making through its management company rather than multiple independent holders.

Corporate Governance Expert

TL;DR: Shared voting/dispositive power among an investment vehicle, its manager, and managing partners is disclosed; no single reporting person claims sole control.

The report clarifies that voting and disposition decisions rest with Andera as manager of BioDiscovery 6 and that Messrs. Bergez and Mauron, as managing partners, may be deemed beneficial owners. The Reporting Persons expressly disclaim group status. The disclosure aligns with governance transparency norms for large passive holdings; it does not indicate a coordinated control change or activism based on the certification language.

FAQ

How many Inventiva (IVA) shares does BioDiscovery 6 report owning?

BioDiscovery 6 reports beneficial ownership of 12,296,295 ordinary shares.

What percentage of Inventiva does the 12,296,295 shares represent?

The shares represent 8.8% of ordinary shares, based on 139,151,274 shares outstanding as of May 7, 2025.

Who holds voting and dispositive power over the reported shares?

Voting and dispositive decisions are exercised by Andera Partners as BioDiscovery 6’s management company; Stephane Bergez and Francois Xavier Mauron are named managing partners with shared power.

Did any Reporting Person claim sole voting or dispositive power?

No. Each Reporting Person reports 0 sole voting power and 0 sole dispositive power and 12,296,295 shared voting and dispositive power.

Does the filing indicate intent to influence control of Inventiva?

No. The Reporting Persons include a certification stating the securities were not acquired to change or influence control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:13 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Inventiva S.A.

(Name of Issuer)

Ordinary Shares, nominal value Euro 0.01 per share

(Title of Class of Securities)

46124U107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 46124U107

1

Names of Reporting Persons

Andera Partners

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,296,295.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,296,295.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,296,295.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 46124U107

1

Names of Reporting Persons

BioDiscovery 6 FPCI

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,296,295.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,296,295.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,296,295.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 46124U107

1

Names of Reporting Persons

Stephane Bergez

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,296,295.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,296,295.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,296,295.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 46124U107

1

Names of Reporting Persons

Francois Xavier Mauron

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,296,295.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,296,295.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,296,295.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inventiva S.A.
(b)	Address of issuer's principal executive offices: 50 rue de Dijon, Daix, I0, 21121 .
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") are: BioDiscovery 6 FPCI ("BioDiscovery 6") Andera Partners ("Andera") Stephane Bergez ("Bergez") Francois Xavier Mauron ("Mauron") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 2 place de Rio de Janeiro 75008 Paris France
(c)	Citizenship: BioDiscovery 6 France Andera France Bergez France Mauron France
(d)	Title of class of securities: Ordinary Shares, nominal value Euro 0.01 per share
(e)	CUSIP No.: 46124U107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. BioDiscovery 6 is the record holder of 12,296,295 ordinary shares. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6. CUSIP Number 46124U107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents one ordinary share of the Issuer. No CUSIP has been assigned to the Issuer's ordinary shares.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 139,151,274 ordinary shares outstanding as of May 7, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on May 5, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Andera Partners

Signature:	/s/ Stephane Bergez
Name/Title:	By Stephane Bergez, Managing Partner
Date:	08/14/2025

BioDiscovery 6 FPCI

Signature:	/s/ Stephane Bergez
Name/Title:	By Andera Partners, its management company, By Stephane Bergez, Managing Partner
Date:	08/14/2025

Stephane Bergez

Signature:	/s/ Stephane Bergez
Name/Title:	Stephane Bergez
Date:	08/14/2025

Francois Xavier Mauron

Signature:	/s/ Francois Xavier Mauron
Name/Title:	Francois Xavier Mauron
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the SEC on April 14, 2025).